InTrack Investment Management Inc Sells 12,548 Shares of Kenvue Inc. (NYSE:KVUE)

InTrack Investment Management Inc decreased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 56.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 9,720 shares of the company’s stock after selling 12,548 shares during the period. InTrack Investment Management Inc’s holdings in Kenvue were worth $209,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of KVUE. Vanguard Group Inc. raised its stake in Kenvue by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 148,880,588 shares of the company’s stock worth $3,205,399,000 after purchasing an additional 2,226,390 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Kenvue by 19.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 109,327,221 shares of the company’s stock valued at $2,353,816,000 after buying an additional 18,118,056 shares during the period. Wellington Management Group LLP boosted its stake in shares of Kenvue by 6.7% in the fourth quarter. Wellington Management Group LLP now owns 76,501,956 shares of the company’s stock valued at $1,647,087,000 after buying an additional 4,815,126 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Kenvue by 9.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 66,665,454 shares of the company’s stock worth $1,435,307,000 after acquiring an additional 5,574,265 shares during the period. Finally, Morgan Stanley raised its holdings in Kenvue by 4,057.4% in the 3rd quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock valued at $625,745,000 after acquiring an additional 30,413,040 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of KVUE opened at $18.24 on Wednesday. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. The stock has a market cap of $34.93 billion, a PE ratio of 23.38, a PEG ratio of 1.93 and a beta of 1.41. Kenvue Inc. has a 12-month low of $17.75 and a 12-month high of $26.60. The business has a 50-day simple moving average of $19.14 and a two-hundred day simple moving average of $19.93.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.25 by $0.03. The company had revenue of $2.89 billion for the quarter, compared to analyst estimates of $3.79 billion. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The business’s revenue for the quarter was down 24.9% on a year-over-year basis. Analysts anticipate that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th were given a dividend of $0.20 per share. The ex-dividend date was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 4.39%. Kenvue’s dividend payout ratio (DPR) is currently 102.56%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on KVUE. HSBC raised their price target on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday, May 8th. Citigroup restated a “neutral” rating and issued a $21.00 target price on shares of Kenvue in a research report on Tuesday, May 28th. William Blair assumed coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. Finally, Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $23.09.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.